Ocean Biomedical (Ocean Biomedical) Cash-to-Debt : 0.00 (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Ocean Biomedical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ocean Biomedical's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Ocean Biomedical couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Ocean Biomedical's Cash-to-Debt or its related term are showing as below:

During the past 4 years, Ocean Biomedical's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.34.

OCEA's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.225
* Ranked among companies with meaningful Cash-to-Debt only.

Ocean Biomedical Cash-to-Debt Historical Data

The historical data trend for Ocean Biomedical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ocean Biomedical Cash-to-Debt Chart

Ocean Biomedical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

N/A

No Debt

0.15

Ocean Biomedical Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial										N/A	0.15	0.04	0.10	-

Competitive Comparison of Ocean Biomedical's Cash-to-Debt

For the Biotechnology subindustry, Ocean Biomedical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocean Biomedical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocean Biomedical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ocean Biomedical's Cash-to-Debt falls into.

Ocean Biomedical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ocean Biomedical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.328	/	(2.15	+	0)
	=	0.15

Ocean Biomedical's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.031	/	(12.051	+	0)
	=	0.00

Ocean Biomedical (NAS:OCEA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ocean Biomedical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ocean Biomedical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocean Biomedical (Ocean Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocean Biomedical Inc (NAS:OCEA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

8AW0:Germany

Address

55 Claverick Street, Room 325, Providence, RI, USA, 02903

Website

https://www.oceanbiomedical.com

Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.

Executives

Robert J Sweeney	officer: Chief Accounting Officer	20298 CRAIGEN CIRCLE, SARATOGA CA 95070
M Michelle Berrey	director	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
William F Owens	director	C/O KEY ENERGY SERVICES, INC., 1301 MCKINNEY STREET, SUITE 1800, HOUSTON TX 77010
Inderjote S Kathuria	officer: Chief Strategy Officer	19W060 AVENUE LATOUR, OAK BROOK IL 60523
Gurinder S Kalra	officer: Chief Financial Officer	2305 WASHINGTON STREET, APT 301, SAN FRANCISCO CA 94115
Chirinjeev Kathuria	director	C/O UPHEALTH HOLDINGS, INC., 14000 S. MILITARY TRAIL #203, DELRAY BEACH FL 33484
Jerome Ringo	director	1731 EMBARCADERO ROAD SUITE 200, PALO ALTO CA 94303
Poseidon Bio, Llc	10 percent owner	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Daniel Behr	officer: EVP, Innov./Acad. P'ships Head	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jack A Elias	director	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Jonathan Kurtis	director	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Elizabeth Ng	director, officer: Chief Executive Officer	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Martin D Angle	director	OCEAN BIOMEDICAL, INC., 55 CLAVERICK ST., ROOM 325, PROVIDENCE RI 02903
Aesther Healthcare Sponsor, Llc	10 percent owner	515 MADISON AVE., SUITE 8078, NEW YORK NY 10022
Michael L Peterson	director	17 CANARY COURT, DANVILLE CA 94526